13 August 2015
Prescription drug prices fall significantly over time because the marketplace is unlike any other part of the U.S. health care system.
Innovator companies invest in pioneering research to bring new treatments to patients, and over time those medicines become available as lower-cost generic copies. Nearly 90 percent of all medicines prescribed to U.S. patients are generics and typically cost up to 80 percent less than the original brand medicine.
This is possible because significant research and development resources are not required for the manufacturing of generic medicines.
The impact of generic medicines is widespread and swift. Newly introduced generics are adopted rapidly and can capture an average of three quarters of the market within 3 months, with some capturing as much as 90 percent.
This is one reason why retail prescription medicines have consistently accounted for just 10 percent of U.S. health care spending, even though more than 500 new medicines have been brought to U.S. patients in the past 15 years. The savings created by generic copies free up resources to invest in new treatments - creating headroom for innovation – and resulting in significant progress against some of the most costly and challenging diseases.
Read more about how our nation’s competitive biopharmaceutical marketplace controls costs while encouraging the development of innovative new medicines here.Prescription drug prices fall significantly over time because the marketplace is unlike any other part of the U.S. health care system.
Innovator companies invest in pioneering research to bring new treatments to patients, and over time those medicines become available as lower-cost generic copies. Nearly 90 percent of all medicines prescribed to U.S. patients are generics and typically cost up to 80 percent less than the original brand medicine.
This is possible because significant research and development resources are not required for the manufacturing of generic medicines.
The impact of generic medicines is widespread and swift. Newly introduced generics are adopted rapidly and can capture an average of three quarters of the market within 3 months, with some capturing as much as 90 percent.
This is one reason why retail prescription medicines have consistently accounted for just 10 percent of U.S. health care spending, even though more than 500 new medicines have been brought to U.S. patients in the past 15 years. The savings created by generic copies free up resources to invest in new treatments - creating headroom for innovation – and resulting in significant progress against some of the most costly and challenging diseases.
Read more about how our nation’s competitive biopharmaceutical marketplace controls costs while encouraging the development of innovative new medicines here.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024